Additionally, the lesion is not likely to have originated through a process related to the patient’s breast cancer diagnosis or treatment as it strongly and diffusely expressed GFAP, it did not express GATA3 (a marker typically detected in breast cancer metastases), and its location was outside of the field of the patient’s previous radiation treatment. This evidence concerns the gene GATA3 and breast carcinoma.